精神分裂症与卒中二级预防药物依从性的关联
在加拿大安大略省2004–2018年基于人群的队列研究中,≥65岁缺血性卒中住院患者共55 842例,其中1.0%患精神分裂症。出院后1年仍存活且3个月内配药者中,精神分裂症患者抗高血压、降脂及抗凝药物的低依从比例均更高,校正后OR约1.60。
要点
- 老年缺血性卒中后精神分裂症患者二级预防药物低依从风险约增60%。
- 抗高血压、降脂、抗凝三类药物低依从比例均显著高于无精神分裂症者。
- 需针对个体与系统层面干预以改善该人群血管风险管理。
核心结论
- 精神分裂症与缺血性卒中后二级预防药物低依从性相关。
研究设计与样本
- 基于人群的队列研究,利用加拿大安大略省行政数据库纳入2004–2018年≥65岁缺血性卒中住院患者55 842例,其中1.0%有精神分裂症。
主要发现
- 出院后1年存活且3个月内配药者中,精神分裂症组抗高血压药物低依从比例为28.0%对18.8%,校正OR 1.60(95%CI 1.28-2.01)。
- 降脂药物低依从比例为38.6%对29.8%,校正OR 1.60(95%CI 1.31-1.96)。
- 抗凝药物低依从比例为41.1%对32.0%,校正OR 1.61(95%CI 1.00-2.58)。
关键数值与推荐
- 低依从定义为年度覆盖天数比例<0.4。
- 校正因素包括年龄、性别、合并症、居住区域及社会经济地位。
临床怎么用
- 对老年缺血性卒中合并精神分裂症患者,应关注并监测其二級预防药物依从性。
- 可考虑个体与系统层面干预以改善该人群血管风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Schizophrenia is associated with an increased risk of stroke and under-treatment of vascular risk factors, but less is known about adherence to medications for secondary stroke prevention. We sought to understand current rates of adherence to secondary stroke prevention therapies among elderly ischemic stroke survivors with and without schizophrenia. METHODS: In a population-based cohort study, we used administrative databases to identify all patients aged ≥65 years who were hospitalized with ischemic stroke in the province of Ontario, Canada, between 2004 and 2018, and a validated algorithm to identify those with schizophrenia. Among patients who filled a prescription for antihypertensive, lipid-lowering, or anticoagulant medications within 3 months and were alive 1 year after discharge, we compared the proportion with low adherence (defined as an annual proportion of days covered of <0.4) in those with and without schizophrenia. We used multivariable logistic regression to estimate the association between schizophrenia and low adherence adjusting for age, sex, comorbid conditions, area of residence, and socioeconomic status. RESULTS: Of the 55 842 patients included, the mean age was 79.5 years, 53.3% were women, and 1.0% had schizophrenia. Among those who survived to 1 year after discharge, individuals with schizophrenia were more likely than those without to have low adherence to antihypertensive (28.0% versus 18.8%; adjusted odds ratio, 1.60 [95% CI, 1.28-2.01]), lipid-lowering (38.6% versus 29.8%; adjusted odds ratio, 1.60 [95% CI, 1.31-1.96]), or anticoagulant medications (41.1% versus 32.0%; adjusted odds ratio, 1.61 [95% CI, 1.00-2.58]), even after adjustment for age, sex, comorbid illness, rurality, and neighborhood income quintile. CONCLUSIONS: Schizophrenia is associated with poor adherence to medications for secondary stroke prevention. Future work should focus on developing individual- and system-level interventions to improve vascular risk factor management in this population.
引用
- Kapoor E, Sheehan KA, Yu AYX, et al. Association Between Schizophrenia and Adherence to Medications for Secondary Stroke Prevention. Stroke. 2025. PMID: 40735774. doi:10.1161/STROKEAHA.125.051100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。